Consistent with our findings, a previous study in patients with SLE, SLE and antiphospholipid syndrome (APS), and primary APS has described the lower expression of miR-128-3p in patients with a high IFN signature relative to patients with a low IFN signature and healthy controls [23]. This evidence concerns the gene IFNA1 and systemic lupus erythematosus.